Show simple item record

dc.contributor.authorKo, Sae Hee
dc.contributor.authorNauta, Allison
dc.contributor.authorMorrison, Shane D.
dc.contributor.authorZhou, Hongyan
dc.contributor.authorZimmermann, Andrew
dc.contributor.authorGurtner, Geoffrey C.
dc.contributor.authorDing, Sheng
dc.contributor.authorLongaker, Michael T.
dc.contributor.editorMcNeil, Paul L.
dc.date.accessioned2012-10-26T16:29:32Z
dc.date.available2012-10-26T16:29:32Z
dc.date.issued2011-11-18en_US
dc.identifier.citationPLoS One. 2011 Nov 18; 6(11):e27844en_US
dc.identifier.issn1932-6203en_US
dc.identifier.pmid22125629en_US
dc.identifier.doi10.1371/journal.pone.0027844en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/685
dc.description.abstractDiabetic wounds remain a major medical challenge with often disappointing outcomes despite the best available care. An impaired response to tissue hypoxia and insufficient angiogenesis are major factors responsible for poor healing in diabetic wounds. Here we show that the antimycotic drug ciclopirox olamine (CPX) can induce therapeutic angiogenesis in diabetic wounds. Treatment with CPX in vitro led to upregulation of multiple angiogenic genes and increased availability of HIF-1α. Using an excisional wound splinting model in diabetic mice, we showed that serial topical treatment with CPX enhanced wound healing compared to vehicle control treatment, with significantly accelerated wound closure, increased angiogenesis, and increased dermal cellularity. These findings offer a promising new topical pharmacologic therapy for the treatment of diabetic wounds.
dc.rightsKo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_US
dc.subjectResearch Articleen_US
dc.subjectBiologyen_US
dc.subjectAnatomy and Physiologyen_US
dc.subjectEndocrine Systemen_US
dc.subjectDiabetic Endocrinologyen_US
dc.subjectSkinen_US
dc.subjectSkin Physiologyen_US
dc.subjectMedicineen_US
dc.subjectAnatomy and Physiologyen_US
dc.subjectEndocrine Systemen_US
dc.subjectDiabetic Endocrinologyen_US
dc.subjectSkinen_US
dc.subjectSkin Physiologyen_US
dc.subjectDermatologyen_US
dc.subjectDermatologic and Cosmetic Surgeryen_US
dc.subjectEndocrinologyen_US
dc.subjectDiabetic Endocrinologyen_US
dc.subjectDiabetes Mellitus Type 2en_US
dc.subjectSurgeryen_US
dc.subjectDermatologic and Cosmetic Surgeryen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntifungal Agentsen_US
dc.subject.meshBlotting, Westernen_US
dc.subject.meshCell Lineen_US
dc.subject.meshDiabetes Mellitusen_US
dc.subject.meshGene Expression Regulationen_US
dc.subject.meshHuman Umbilical Vein Endothelial Cellsen_US
dc.subject.meshHumansen_US
dc.subject.meshHypoxia-Inducible Factor 1, alpha Subuniten_US
dc.subject.meshMiceen_US
dc.subject.meshNIH 3T3 Cellsen_US
dc.subject.meshNeovascularization, Physiologicen_US
dc.subject.meshPyridonesen_US
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_US
dc.subject.meshSkinen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshVascular Endothelial Growth Factor Aen_US
dc.subject.meshWound Healingen_US
dc.titleAntimycotic Ciclopirox Olamine in the Diabetic Environment Promotes Angiogenesis and Enhances Wound Healingen_US
dc.typeArticleen_US
dc.identifier.pmcidPMC3220686en_US
dc.contributor.corporatenameDepartment of Cellular Biology and Anatomy
dc.contributor.corporatenameCollege of Graduate Studies
refterms.dateFOA2019-04-10T00:32:25Z
html.description.abstractDiabetic wounds remain a major medical challenge with often disappointing outcomes despite the best available care. An impaired response to tissue hypoxia and insufficient angiogenesis are major factors responsible for poor healing in diabetic wounds. Here we show that the antimycotic drug ciclopirox olamine (CPX) can induce therapeutic angiogenesis in diabetic wounds. Treatment with CPX in vitro led to upregulation of multiple angiogenic genes and increased availability of HIF-1α. Using an excisional wound splinting model in diabetic mice, we showed that serial topical treatment with CPX enhanced wound healing compared to vehicle control treatment, with significantly accelerated wound closure, increased angiogenesis, and increased dermal cellularity. These findings offer a promising new topical pharmacologic therapy for the treatment of diabetic wounds.


Files in this item

Thumbnail
Name:
pone.0027844.pdf
Size:
637.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record